-
1دورية أكاديمية
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
-
2دورية أكاديمية
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
-
3دورية أكاديمية
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
-
4دورية أكاديمية
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
-
5صورة
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
-
6صورة
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
-
7صورة
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
-
8صورة
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
العلاقة: https://figshare.com/articles/figure/The_humoral_immune_response_induced_by_SARS-CoV-2_/14156666Test
-
9
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
-
10
المؤلفون: María Elvira Balcells (10225442), Luis Rojas (3281562), Nicole Le Corre (9593588), Constanza Martínez-Valdebenito (4248742), María Elena Ceballos (10225445), Marcela Ferrés (252888), Mayling Chang (10225448), Cecilia Vizcaya (10225451), Sebastián Mondaca (10225454), Álvaro Huete (10225457), Ricardo Castro (3827620), Mauricio Sarmiento (10225460), Luis Villarroel (3060045), Alejandra Pizarro (10225463), Patricio Ross (10225466), Jaime Santander (10225469), Bárbara Lara (10225472), Marcela Ferrada (10225475), Sergio Vargas-Salas (10225478), Carolina Beltrán-Pavez (10225481), Ricardo Soto-Rifo (715807), Fernando Valiente-Echeverría (382203), Christian Caglevic (10225484), Mauricio Mahave (10225487), Carolina Selman (10225490), Raimundo Gazitúa (10225493), José Luis Briones (10225496), Franz Villarroel-Espindola (6093377), Carlos Balmaceda (1614934), Manuel A. Espinoza (10225499), Jaime Pereira (659972), Bruno Nervi (321975)
مصطلحات موضوعية: Medicine, Biotechnology, Developmental Biology, Cancer, Science Policy, Virology, trial Background Convalescent plasma, CP therapy, randomized phase II, PCR clearance rate, ventilation, COVID -19 symptom onset, 58 randomized patients, CP group, plasma group, CI, hospitalization, Trial registration NCT 04375098, outcome, COVID -19 progression, in-hospital mortality rate, anti-SARS-CoV -2 convalescent plasma
العلاقة: https://figshare.com/articles/dataset/Primary_and_secondary_clinical_outcomes_/14156672Test